Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer

<p>Mechanistic link between LKB1 and PARP1. (a) A bioinformatics tool (Pepsite) was utilized to predict the possibility of PARP1 docking on the di-Arg ER retention motif of LKB1 (PRR). (b) Localization of PARP1 (green) relative to LKB1 (red) in LKB1-WT A549 cells and H1299 cells. Scale bar = 2...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
1. autor:	Li-Li Long (14963775) (author)
Kolejni autorzy:	Si-Cong Ma (14963778) (author), Ze-Qin Guo (14963781) (author), Yan-Pei Zhang (14963784) (author), Zhenzhen Fan (14963787) (author), Li-Juan Liu (14963790) (author), Li Liu (12292657) (author), Duan-Duan Han (14963793) (author), Meng-Xin Leng (14963796) (author), Jian Wang (14963799) (author), Xue-Jun Guo (14963802) (author), Jia-Le Tan (14963805) (author), Xiao-Ting Cai (14963808) (author), Yan Lin (14963811) (author), Xinghua Pan (14963814) (author), De-Hua Wu (14963817) (author), Xue Bai (14963820) (author), Zhong-Yi Dong (11855458) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Tumor Biology Molecular and Cellular Biology Immuno-oncology DNA Damage and Repair DNA repair Immunotherapy Combination immunotherapy Lung Cancer Tumor Microenvironment Immune cells and the microenvironment
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
od: Li-Li Long (14963775)
Wydane: (2025)

Figure 1 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 2 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 3 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 4 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 5 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 6 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Macros for image quantification from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Supplementary Data 2 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Supplementary Data 3 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Supplementary Data 4 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Supplementary Data 5 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
od: Massimiliano Mellone (14959419)
Wydane: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
od: Katrina M. Lappin (9340394)
Wydane: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
od: Katrina M. Lappin (9340394)
Wydane: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
od: Katrina M. Lappin (9340394)
Wydane: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
od: Katrina M. Lappin (9340394)
Wydane: (2025)

Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
od: Holly Tovey (16824233)
Wydane: (2025)

Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
od: Holly Tovey (16824233)
Wydane: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
od: Arun Kanakkanthara (14937731)
Wydane: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
od: Arun Kanakkanthara (14937731)
Wydane: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
od: Long Jiang (14956159)
Wydane: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
od: Long Jiang (14956159)
Wydane: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
od: Long Jiang (14956159)
Wydane: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
od: Andrew Nguyen (17142197)
Wydane: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
od: Andrew O. Yam (15293045)
Wydane: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
od: Isha Mondal (16721699)
Wydane: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
od: Craig M. Goodwin (14955973)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_qd5knk6qhaov8dnfmbr78oqbu0